First Foundation Advisors Position in Pfizer INC (PFE) Has Trimmed by $17.72 Million as Stock Declined

March 13, 2018 - By Richard Conner

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It increased, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. Rocky Mountain Advisers Ltd Liability Company invested in 118 shares. Pictet Asset Mgmt owns 4.88M shares. First Eagle Mgmt Ltd Liability owns 66,061 shares or 0.01% of their US portfolio. Iguana Health Mgmt Lc accumulated 60,000 shares. State Of New Jersey Common Pension Fund D holds 0.73% of its portfolio in Pfizer Inc. (NYSE:PFE) for 5.10 million shares. Platinum Investment Mngmt accumulated 47,610 shares. Bontempo Ohly Ltd Limited Liability Company, Maryland-based fund reported 98,305 shares. Redmond Asset Mngmt Limited Co invested 0.19% in Pfizer Inc. (NYSE:PFE). Independent Inc has invested 0.42% of its portfolio in Pfizer Inc. (NYSE:PFE). Magellan Asset Management invested in 0% or 810 shares. Bush Odonnell Advisors Inc has 6,944 shares for 0.19% of their portfolio. Prescott Ltd Limited Liability Company reported 6,000 shares. Mairs Pwr holds 2.04% or 4.77M shares. Woodmont Invest Counsel Limited Liability Corp, Tennessee-based fund reported 70,027 shares. American Retail Bank accumulated 164,342 shares or 1.76% of the stock.

Since December 15, 2017, it had 0 insider buys, and 10 sales for $10.15 million activity. Dolsten Mikael had sold 13,986 shares worth $501,398. SUSMAN SALLY also sold $1.24M worth of Pfizer Inc. (NYSE:PFE) shares. 9,510 Pfizer Inc. (NYSE:PFE) shares with value of $353,677 were sold by LUND-JURGENSEN KIRSTEN. Shares for $249,750 were sold by MACKENZIE ALEXANDER R on Friday, December 15. Shares for $64,679 were sold by CORNWELL W DON on Monday, February 26. Shares for $296,560 were sold by JOHNSON RADY A on Friday, December 15.

First Foundation Advisors decreased its stake in Pfizer Inc (PFE) by 33.93% based on its latest 2017Q3 regulatory filing with the SEC. First Foundation Advisors sold 506,230 shares as the company’s stock declined 3.45% while stock markets rallied. The hedge fund held 985,632 shares of the health care company at the end of 2017Q3, valued at $35.19M, down from 1.49M at the end of the previous reported quarter. First Foundation Advisors who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $217.76B market cap company. The stock decreased 0.08% or $0.03 during the last trading session, reaching $36.58. About 11.10 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since March 13, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

First Foundation Advisors, which manages about $3.20 billion and $1.76 billion US Long portfolio, upped its stake in Macerich Co (NYSE:MAC) by 148,295 shares to 433,667 shares, valued at $23.84M in 2017Q3, according to the filing. It also increased its holding in Level 3 Communications Inc (NYSE:LVLT) by 206,164 shares in the quarter, for a total of 972,291 shares, and has risen its stake in British American Tobacco Plc A (NYSEMKT:BTI).

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on May, 1. They expect $0.70 EPS, up 1.45 % or $0.01 from last year’s $0.69 per share. PFE’s profit will be $4.17B for 13.06 P/E if the $0.70 EPS becomes a reality. After $0.62 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts 12.90 % EPS growth.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Better Buy: Novavax, Inc. vs. Pfizer Inc.” on February 23, 2018, also with their article: “Pfizer: All Of A Sudden Looking Cheap?” published on March 12, 2018, published: “Pfizer Might Be Just What The Doctor Ordered” on March 08, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: and their article: “Biogen to buy schizophrenia treatment from Pfizer for up to $590 million” published on March 12, 2018 as well as‘s news article titled: “Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY)” with publication date: February 12, 2018.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 22 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pfizer had 75 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 31 by Piper Jaffray. The company was maintained on Monday, February 26 by Jefferies. On Monday, July 10 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Hold” rating by Jefferies on Thursday, October 13. Argus Research downgraded the stock to “Hold” rating in Wednesday, November 2 report. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, September 5. As per Tuesday, November 21, the company rating was maintained by BMO Capital Markets. Jefferies maintained the stock with “Hold” rating in Monday, October 16 report. The stock of Pfizer Inc. (NYSE:PFE) earned “Overweight” rating by Morgan Stanley on Wednesday, September 20. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) rating on Friday, August 28. Piper Jaffray has “Overweight” rating and $48 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: